[{"id":"791ed3e1-159a-4669-b6a9-9650c77c7e2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05079698","created_at":"2021-10-15T14:53:06.706Z","updated_at":"2025-02-25T15:54:10.535Z","phase":"Phase 1","brief_title":"A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer","source_id_and_acronym":"NCT05079698","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-03"},{"id":"5b3663eb-53d2-4913-aef6-1eb4ef0d39c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084338","created_at":"2023-10-16T15:12:50.854Z","updated_at":"2025-02-25T17:39:27.404Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc","source_id_and_acronym":"NCT06084338","lead_sponsor":"VA Office of Research and Development","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 11/29/2027","primary_completion_date":" 11/29/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-12-30"},{"id":"8247cdb4-7bc6-434e-8424-d805cacb6db9","acronym":"LuCAB","url":"https://clinicaltrials.gov/study/NCT05340374","created_at":"2022-04-22T14:53:47.311Z","updated_at":"2025-02-25T17:37:46.899Z","phase":"Phase 1/2","brief_title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05340374 - LuCAB","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 06/20/2026","primary_completion_date":" 06/20/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-11-08"},{"id":"df0d9226-3a47-4f82-892f-731646017c46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04996602","created_at":"2021-08-09T13:53:09.588Z","updated_at":"2024-07-02T16:36:07.278Z","phase":"Phase 1","brief_title":"Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC","source_id_and_acronym":"NCT04996602","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression • FOLH1 overexpression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression • FOLH1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/14/2019","start_date":" 01/14/2019","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-15"}]